A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer

被引:10
作者
Gauvin, A
Pinguet, F
Culine, S
Astre, C
Gomeni, R
Bressolle, F
机构
[1] Univ Montpellier 1, Fac Pharm, Clin Pharmacokinet Lab, F-34093 Montpellier, France
[2] Inst Canc Res, Oncopharmacol Dept, Serv Pharm, F-34298 Montpellier, France
[3] Inst Canc Res, Dept Med, F-34298 Montpellier, France
关键词
limited-sampling strategy; population pharmacokinetics; vinorelbine;
D O I
10.1097/00001813-200206000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to characterize the population pharmacokinetic of vinorelbine In elderly patients and to propose a limited-sampling strategy to estimate individual pharmacokinetic parameters. Vinorelbine was administered by a 10-min continuous infusion at a dose of 20-30 mg/m(2). The population parameters were computed, using a three-compartment model, from an initial group of 27 patients. Twelve additional courses were used for model validation and evaluation of eight different limited-sampling strategies. The inter-individual variability of CL was explained by a linear dependency with age. The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.61 (64%), k(21)=0.776 h(-1) (20%), k(31)=0.0346h(-1) (15.2%), alpha=0.431 h(-1) (6.84%) and beta=0.0167 h(-1) (25%). Bayesian estimation with three measured levels (end of infusion, and 6 and 48 h) can be selected, because it allows adequate estimation of CL, elimination half-life and vinorelbine concentrations with a non-significant bias. Moreover, the choice of these three sampling times presents practicality advantages for the patient's comfort. Vinorelbine clearance decreasing with age and AUC being a good predictor of several toxicity end points during vinorelbine treatment, the limited-sampling strategy developed in this paper may be clinically relevant. [(C) 2002 Lippincott Williams Wilkins.].
引用
收藏
页码:473 / 480
页数:8
相关论文
共 28 条
[1]   EXPERIMENTAL-DESIGN AND EFFICIENT PARAMETER-ESTIMATION IN POPULATION PHARMACOKINETICS [J].
ALBANNA, MK ;
KELMAN, AW ;
WHITING, B .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1990, 18 (04) :347-360
[2]  
BEAL SL, 1992, NONMEM USERS GUIDE
[3]   PHARMACOKINETICS OF A NEW ANTICANCER DRUG, NAVELBINE, IN PATIENTS - COMPARATIVE-STUDY OF RADIOIMMUNOLOGIC AND RADIOACTIVE DETERMINATION METHODS [J].
BORE, P ;
RAHMANI, R ;
VANCANTFORT, J ;
FOCAN, C ;
CANO, JP .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 (04) :247-251
[4]  
Buccheri G, 2000, CANCER-AM CANCER SOC, V88, P2677, DOI 10.1002/1097-0142(20000615)88:12<2677::AID-CNCR5>3.0.CO
[5]  
2-B
[6]  
ENDRENYI L, 1981, KINETIC DATA ANAL DE, P137
[7]  
FELLOUS A, 1989, SEMIN ONCOL, V16, P9
[8]  
Gauvin A, 2000, CLIN CANCER RES, V6, P2690
[9]   High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: application to a pharmacokinetic study [J].
Gauvin, AL ;
Pinguet, F ;
Poujol, S ;
Astre, C ;
Bressolle, F .
JOURNAL OF CHROMATOGRAPHY B, 2000, 748 (02) :389-399
[10]   Underrepresentation of patients 65 years of age or older in cancer-treatment trials. [J].
Hutchins, LF ;
Unger, JM ;
Crowley, JJ ;
Coltman, CA ;
Albain, KS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (27) :2061-2067